Building on joint research from University of Vienna and Medical University of Vienna, P4 is creating next-generation platinum chemotherapy with fewer side-effects than current approaches.
University of Vienna and Medical University of Vienna teamed up today to spin out Austria-based chemotherapy developer P4 Therapeutics, with the ambition of creating new platinum-based drugs.
P4 Therapeutics will advance pre-clinical research indicating the platinum compound albuplatin could serve as the basis for a chemotherapy that produces fewer side effects than the medications available to oncologists at present.
Despite advances in genetics and immunotherapy, chemotherapies remain an important front-line tool in combatting cancer, although their sheer toxicity…
